|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.
A proof of concept study of the efficacy and safety of oral LAT8881 in acute migraine
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
100 Clinical Results associated with Lateral Pharma Pty Ltd.
0 Patents (Medical) associated with Lateral Pharma Pty Ltd.
100 Deals associated with Lateral Pharma Pty Ltd.
100 Translational Medicine associated with Lateral Pharma Pty Ltd.